Clinical trial data indicates that repeated dosing of psilocybin demonstrates therapeutic potential for reducing symptoms in patients with obsessive-compulsive disorder.
New guidelines indicate that while combining medications with CBT-I may benefit some patients, CBT-I alone is often the preferred treatment for chronic insomnia.
Fluorine-modified antisense oligonucleotides effectively target C9ORF72 repeat RNA to reduce toxicity in frontotemporal dementia and ALS, offering a potential therapeutic strategy for these neurodegenerative conditions.
This study identifies a frontotemporal dementia-like phenotype in schizophrenia linked to striatal dopamine and iron accumulation, offering mechanistic insights for targeting neurodegenerative pathways in psychosis.
A nationwide study reveals that only 40.2% of pregnant women with opioid use disorder receive medication for OUD, highlighting significant gaps in evidence-based prescribing despite MOUD being the gold standard.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Sep 09 – Apr 25)
- AXS-05 (dextromethorphan-bupropion) shows promise for reducing agitation and preventing relapse in Alzheimer disease pending its April 2026 PDUFA decision.
- Monitor clozapine plasma levels closely when co-prescribing valproic acid, as the combination can reduce norclozapine exposure by nearly 50% and lower neutrophil counts.
- Antipsychotic-induced weight gain within the first 12 weeks is a critical predictor of long-term obesity and should trigger immediate lifestyle or pharmacologic intervention.
- Exercise caution when combining SSRIs with antipsychotics due to an elevated risk of cardiac adverse events requiring enhanced cardiovascular monitoring.
- Consider neuroimaging biomarkers for baseline functional connectivity in adolescent MDD, as specific patterns may predict antidepressant response with high accuracy.
- Review the CME guidance on antidepressant selection for patients with neurological disorders or organ failure to optimize dosing and minimize seizure risks.
- Be aware that GLP-1 receptor agonists are emerging as potential repurposed treatments targeting biological drivers of Alzheimer disease.
- Note that the D-amino acid oxidase inhibitor luvadaxistat failed to improve cognitive function in schizophrenia during the Phase 2 ERUDITE trial.
- Recognize that the FDA is accelerating review pathways for psychedelic therapies like psilocybin and methylone through priority vouchers and fast-track designations.
Drug Development 3
The FDA has granted fast-track status to psilocybin and methylone, signaling regulatory progress for these psychedelics in psychiatric treatment development.
PBPK modeling offers a critical tool for optimizing antidepressant dosing in pregnancy to account for physiological changes, though its direct clinical utility remains an emerging area of practice.
Diagnosis & Treatment 4
This CME article outlines evidence-based antidepressant selection and safety considerations—specifically regarding drug interactions, organ dosing, and seizure thresholds—for treating depression in patients with neurological disorders, organ failure, transplants, and reproductive transitions.
Weight gain occurring within the first 12 weeks of antipsychotic treatment is identified as the primary predictor of long-term obesity, highlighting a critical window for early intervention in psychosis care.
This study identifies distinct patterns of self-awareness regarding gesture behavior in schizophrenia versus depression, suggesting that integrating self-report measures with objective assessments is critical for tailoring social communication interventions.
This retrospective cohort study identifies strong associations between Hallucinogen Persisting Perception Disorder (HPPD) and pre-existing anxiety, functional somatic syndromes, and psychiatric comorbidities, highlighting the need for comprehensive clinical assessment in patients presenting with visual disturbances.
Mechanism of Action 1
This study elucidates the molecular mechanisms behind the entourage effect of psilocybin-producing mushrooms, offering critical insights into their pharmacodynamics as a potential psychiatric treatment.
Substance Use 2
A new survey estimates 8 million Americans used psilocybin in 2024, highlighting a significant rise in the use of this psychedelic substance with potential implications for future psychiatric treatment and safety monitoring.
This study characterizes purchasing patterns of low-alcohol beverages in Great Britain, identifying distinct consumer subgroups with varying alcohol risk profiles to inform public health strategies for Substance Use.
Policy & Regulation 5
The FDA is accelerating development and review timelines for psychedelic therapies targeting depression, PTSD, and alcohol use disorder through priority vouchers and IND clearances while preparing specific guidance to address prior methodological gaps in trial design.
The FDA has granted priority review vouchers to three companies for psychedelic treatments targeting treatment-resistant depression and PTSD, signaling accelerated regulatory pathways for these emerging psychotropics.
The FDA has awarded three fast-track vouchers to unspecified psychedelic companies, signaling regulatory support for drug development in this therapeutic area.
The FDA has awarded Priority Review Vouchers to Otsuka, Compass, and Usona for their psychedelic drug candidates, a regulatory milestone that accelerates the review timeline for these potential psychiatric treatments.
The FDA has issued Fast Track vouchers to three companies developing psychedelic medications, a regulatory action designed to accelerate the review process for potential new psychotropic treatments.
Clinical Pearl 3
First responders with PTSD are participating in a psilocybin clinical trial in Arizona, representing a potential new treatment avenue for this high-risk occupational group.
First responders with PTSD are participating in a clinical trial investigating the efficacy of psilocybin for treating post-traumatic stress disorder.
A randomized trial is evaluating intranasal dexmedetomidine as a potential treatment for acute anxiety states in adults.
Podcast Summary 1
Neuroscience 3
This study identifies childhood trauma-specific functional connectome disruptions in adolescent MDD and demonstrates that baseline connectivity patterns can predict antidepressant response with 82% accuracy, supporting the use of neuroimaging biomarkers for precision treatment.
This fMRI study demonstrates that augmenting extinction training with counterconditioning strengthens neural safety representations in PTSD, offering a potential mechanism to enhance exposure therapy efficacy.
This fMRI study identifies distinct neural response patterns to reward uncertainty in adolescents with mood and anxiety symptoms, linking blunted striatal responses during expectancy to anxiety severity and default network activation to anhedonia.